European collaborative project on TArgeted therapy in Renal cell cancer: GEnetic and Tumour-related biomarkers for response and toxicity

Trial Profile

European collaborative project on TArgeted therapy in Renal cell cancer: GEnetic and Tumour-related biomarkers for response and toxicity

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 09 Sep 2016

At a glance

  • Drugs Pazopanib (Primary) ; Sunitinib (Primary) ; Antineoplastics
  • Indications Renal cancer; Renal cell carcinoma
  • Focus Biomarker; Therapeutic Use
  • Acronyms EuroTARGET; EuT-PK-PD
  • Most Recent Events

    • 28 Jan 2016 Status changed from recruiting to active, no longer recruiting as per United Kingdom Clinical Research Network record.
    • 31 Mar 2015 Accrual to date is 99% according to United Kingdom Clinical Research Network record.
    • 20 Mar 2015 Accrual to date is 57% according to United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top